DiaMedica Therapeutics Inc. Company Review & Valuation

OTC Markets
Latest Price

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases.

The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

It is also developing DM199 for the treatment vascular dementia.

In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis.

The company was formerly known as DiaMedica Inc.

and changed its name to DiaMedica Therapeutics Inc.

in December 2016.

DiaMedica Therapeutics Inc.

was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

HQ Location
Minneapolis, Minnesota

Stock Price

Price data not available for DiaMedica Therapeutics Inc..


Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top


Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl